Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCB | P05771 | 6/20 | 0.55 |
| ▸ | PRKCA | P17252 | 5/20 | 0.55 |
| ▸ | PRKCH | P24723 | 3/20 | 0.55 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.55 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.55 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.55 |
| ▸ | CDK4 | P11802 | 3/20 | 0.55 |
| ▸ | CCND1 | P24385 | 3/20 | 0.55 |
| ▸ | CDK2 | P24941 | 3/20 | 0.55 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.55 |
| ▸ | ABL1 | P00519 | 2/20 | 0.55 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.55 |
| ▸ | PRKACA | P17612 | 2/20 | 0.55 |
| ▸ | PRKACG | P22612 | 2/20 | 0.55 |
| ▸ | PRKACB | P22694 | 2/20 | 0.55 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.55 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.55 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.55 |
| ▸ | PRKCG | P05129 | 1/20 | 0.55 |
| ▸ | CDK1 | P06493 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3148490 | 0.81 | PRKCB (0.84) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL2193011 | 0.78 | PIK3CD (0.70) | PRKCQPRKACAPRKD3PIK3CDKDR | |
| SCHEMBL29712113 | 0.78 | PIK3CD (0.70) | PRKCQPRKACAPRKD3PIK3CDKDR | |
| SCHEMBL10714441 | 0.78 | GSK3B (0.51) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL27725234 | 0.75 | PIK3CD (0.66) | PRKCQPRKACAPRKD3PIK3CDKDR | |
| SCHEMBL6322730 | 0.75 | PIK3CD (0.61) | PRKCQPRKACAPRKD3PIK3CDKDR | |
| SCHEMBL10945814 | 0.74 | PIK3CD (0.75) | PRKCQPRKACAPRKD3PIK3CDKDR | |
| SCHEMBL114611 | 0.74 | PTGS2 (0.67) | GSK3BPTGS2 | |
| SCHEMBL6030821 | 0.73 | PRKCB (0.68) | PRKCBPRKCAPRKCHPRKCEPRKCQ | |
| SCHEMBL6321711 | 0.72 | ASH1L (0.60) | PRKCQABL1PRKACAPRKD3PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11045449-B2 | 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment | Johannes Gutenberg-Universität Mainz (DE) | 2021-06-29 | — | — | US | disclosed |
| US-20200253930-A1 | 3-(5-Fluoroindolyl)-4-arylmaleimide Compounds and their Use in Tumor Treatment | UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ (DE) | 2020-08-13 | — | — | US | disclosed |
| EP-3397632-B1 | 3-(5-FLUOROINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | UNIV MAINZ JOHANNES GUTENBERG (DE) | 2020-06-24 | — | — | EP | disclosed |
| EP-3397632-A1 | 3-(5-FLUOROINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | Johannes-Gutenberg-Universität Mainz (DE) | 2018-11-07 | — | — | EP | disclosed |
| WO-2017114863-A1 | 3-(5-FLUOROINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | Johannes Gutenberg-Universität Mainz (DE) | 2017-07-06 | — | — | WO | disclosed |
| EP-3187495-A1 | 3-(5-FLUOROINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | Johannes Gutenberg-Universität Mainz (DE) | 2017-07-05 | — | — | EP | disclosed |
| EP-2655359-B1 | CONJUGATED 3-(INDOLYL)- AND 3-(AZAINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | Johannes-Gutenberg-Universität Mainz (DE) | 2017-03-22 | — | — | EP | disclosed |
| US-9364459-B2 | 3-(indolyl)- or 3-(azaindolyl)- 4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma | Johannes Gutenberg-Universität Mainz (DE) | 2016-06-14 | — | — | US | disclosed |
| EP-2512469-B1 | 3-(INDOLYL)-OR 3-(AZAINDOLYL)- 4-ARYLMALEIMIDE DERIVATIVES FOR USE IN THE TREATMENT OF COLON AND GASTRIC ADENOCARZINOMA | JOHANNES GUTENBERG UNIVERSITÄT MAINZ (DE) | 2016-03-02 | — | — | EP | disclosed |
| EP-2513089-B1 | 3-(INDOLYL)- OR 3-(AZAINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | JOHANNES GUTENBERG UNIVERSITÄT MAINZ (DE) | 2015-09-09 | — | — | EP | disclosed |
| EP-2474541-A1 | Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment | Johannes- Gutenberg-Universität Mainz (DE) | 2012-07-11 | — | — | EP | disclosed |
| WO-2012084683-A1 | CONJUGATED 3-(INDOLYL)- AND 3-(AZAINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | Johannes Gutenberg-Universität Mainz (DE) | 2012-06-28 | — | — | WO | disclosed |
| US-8008320-B2 | 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors | Johannes Gutenberg-Universitatis (DE) | 2011-08-30 | — | — | US | disclosed |
| EP-2343291-A1 | 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment | Johannes Gutenberg-Universität Mainz (DE) | 2011-07-13 | — | — | EP | disclosed |
| EP-2338486-A1 | 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma | Johannes Gutenberg-Universität Mainz (DE) | 2011-06-29 | — | — | EP | disclosed |
| WO-2011073091-A1 | 3-(INDOLYL)-OR 3-(AZAINDOLYL)- 4-ARYLMALEIMIDE DERIVATIVES FOR USE IN THE TREATMENT OF COLON AND GASTRIC ADENOCARZINOMA | Johannes Gutenberg-Universität Mainz (DE) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011073092-A1 | 3-(INDOLYL)- OR 3-(AZAINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT | Johannes Gutenberg-Universität Mainz (DE) | 2011-06-23 | — | — | WO | disclosed |
| US-20090306124-A1 | 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS | JOHANNES GUTENBERG-UNIVERSITAT MAINZ (DE) | 2009-12-10 | — | — | US | disclosed |
| EP-1819697-A1 | 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS | Johannes Gutenberg-Universität Mainz (DE) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006061212-A1 | 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS | Johannes Gutenberg-Universität Mainz (DE) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306124-A1 | 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS | FLT4, KDR, FLT1 | PRKCB 4118/4885PRKCA 4447/4885PRKCH 3641/4885 |
| US-20200253930-A1 | 3-(5-Fluoroindolyl)-4-arylmaleimide Compounds and their Use in Tumor Treatment | FLT4, GSK3B, FLT1 | PRKCB 242/4885PRKCA 342/4885PRKCH 188/4885 |
| US-11045449-B2 | 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment | FLT4, GSK3B, FLT1 | PRKCB 242/4885PRKCA 342/4885PRKCH 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.